Gain Therapeutics, Inc. (GANX) is trading at $1.80 down 1.10% over the past 24 hours. Its Galaxy Score is 30.1, LunarCrush's combined measure of market and social performance. Over the last 24 hours it has seen 117 engagements and 7 posts with 99% positive social sentiment.
AI summary: Gain Therapeutics GT-02287 IND clearance advances to Phase 2 for Parkinson's disease. Positive IND news sparks optimism but near-term selling pressure and liquidity/dilution concerns likely cap upside, keeping GANX range-bound.